Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 9;63(2):181-190.
doi: 10.1002/jmd2.12268. eCollection 2022 Mar.

Very long-chain acyl-CoA dehydrogenase deficiency in a Swedish cohort: Clinical symptoms, newborn screening, enzyme activity, and genetics

David Olsson  1 , Michela Barbaro  2   3 , Charlotte Haglind  1 , Maria Halldin  1 , Svetlana Lajic  1 , Sara Tucci  4 , Rolf H Zetterström  2   3 , Anna Nordenström  1   2
Affiliations

Very long-chain acyl-CoA dehydrogenase deficiency in a Swedish cohort: Clinical symptoms, newborn screening, enzyme activity, and genetics

David Olsson et al. JIMD Rep. .

Abstract

Very long-chain acyl-CoA dehydrogenase deficiency (VLCADD) is a recessive disorder of fatty acid beta-oxidation with variable phenotype. Patients may present during the neonatal period with lethal multi-organ failure or during adulthood with a myopathic phenotype. VLCADD is included in the Swedish newborn screening (NBS) program since 2010. The study describes the phenotype and biochemical findings in relation to the genotype, enzyme activity, and screening data in a Swedish cohort of pediatric patients with VLCADD. A total of 22 patients (20 diagnosed via NBS between 2010 and 2019, two diagnosed pre NBS) were included. Parameters analyzed were enzyme activity (palmitoyl CoA oxidation rate); ACADVL genotype; NBS results including Collaborative Laboratory Integrated Reports (CLIR) score; biochemical findings; treatment; clinical outcome. A clinical severity score (CSS) was compiled using treatment interventions and clinical symptoms. A possible correlation between CSS and VLCAD residual enzyme activity and NBS CLIR score was analyzed. The most common ACADVL variant (c.848T>C) was identified in 24/44 alleles. Five novel variants were detected. Clinical manifestations varied from asymptomatic to severe. There was a correlation between CSS, residual enzyme activity, and CLIR scores. Most patients diagnosed via NBS had less severe disease compared to those clinically diagnosed. In conclusion, the identified correlation between the NBS CLIR score, residual enzyme activity, and clinical outcome suggests that information available neonatally may aid in treatment decisions.

Keywords: Sweden; clinical outcome; newborn screening; very long‐chain acyl‐CoA dehydrogenase deficiency (VLCADD).

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interests.

Figures

FIGURE 1
FIGURE 1
Cohort BMI standard deviation score
FIGURE 2
FIGURE 2
Correlation between CSS, CLIR score, and residual enzyme activity in patient lymphocytes. (A) Spearman’s rho correlation coefficient 0.486, p = 0.043. (B) Spearman’s rho correlation coefficient −0.830, p = 0.016. (C) Spearman’s rho correlation coefficient −0.769, p = 0.003
See this image and copyright information in PMC

References

    1. Aoyama T, Uchida Y, Kelley RI, et al. A novel disease with deficiency of mitochondrial very‐long‐chain acyl‐CoA dehydrogenase. Biochem Biophys Res Commun. 1993;191(3):1369‐1372. - PubMed
    1. Andresen BS, Olpin S, Poorthuis BJHM, et al. Clear correlation of genotype with disease phenotype in very‐long‐chain acyl‐CoA dehydrogenase deficiency. Am J Hum Genet. 1999;64(2):479‐494. - PMC - PubMed
    1. Baruteau J, Sachs P, Broué P, et al. Clinical and biological features at diagnosis in mitochondrial fatty acid beta‐oxidation defects: a French pediatric study of 187 patients. J Inherit Metab Dis. 2013;36(5):795‐803. - PubMed
    1. Baruteau J, Sachs P, Broué P, et al. Clinical and biological features at diagnosis in mitochondrial fatty acid beta‐oxidation defects: a French pediatric study from 187 patients. J Inherit Metab Dis. 2014;37(1):137‐139. - PubMed
    1. Spiekerkoetter U, Lindner M, Santer R, et al. Management and outcome in 75 individuals with long‐chain fatty acid oxidation defects: results from a workshop. J Inherit Metab Dis. 2009;32(4):488‐497. - PubMed